FDA is advising that these 2 opioid addiction medications should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system.
Formulary Watch
Latest News
All News
Advertisement
While FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.
FDA warned about an injunction or seizure if Meridian Medical Technologies, a division of Pfizer, does not correct its problems with the EpiPen (epinephrine auto-injector).
An increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.
A top-selling diabetes drug has gained a cardiovascular indication from FDA.
New biosimilars may harm the sales of this autoimmune blockbuster.
FDA approved a targeted new drug to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
An FDA committee will review prescription opioid products containing hydrocodone or codeine to treat coughs in children.
Pharmacy and medical organizations lauded a new class action lawsuit against CVS Health and Walgreens, alleging the two pharmacy chains colluded with pharmacy benefit managers (PBMs) to drive up the cost of generic drugs.
FDA warned consumers and health care professionals not to use a certain brand of drugs and dietary supplements that are contaminated.
Advertisement
The Drug Enforcement Administration wants to slash the production of opioid painkillers by 20% in 2018.
FDA approved the first treatment for patients with a certain type of acute myeloid leukemia, as well as 2 new drugs to treat hepatitis C.
Novo Nordisk’s DEVOTE study reveals interesting findings.
FDA approves new diagnostic test for non-small cell lung cancer.
FDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
FDA approved the use of a new fluoroquinolone antibiotic to treat ABSSSI.
Potential public health consquences prompts FDA to request removal of opioid pain medication.
Adamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.
The first generic Truvada for treating and preventing HIV will be available, but when?
FDA approves Isentress at a higher dose for HIV-1 infected patients.
A new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
FDA has approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.
Lilly's galcanezumab proves successful in three phase 3 migraine studies. Here are the findings.
AstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
FDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.
The 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
3
Biosimilar competition could surpass IRA-negotiated savings by year three
4
Midlife influenza vaccine not associated with increased risk of Parkinson’s disease, study shows
5
